Table 1.
Patients and treatments characteristics
| Age (y) | ||
| Median (range) | 67 | 44-87 |
| PSA at diagnosis (ng/mL) | ||
| Median (range) | 8.1 | 0.2-132 |
| AJCC tumor classification (N, %) | ||
| T1 | 1126 | 64 % |
| T2 | 627 | 32 % |
| T3 | 80 | 4 % |
| Gleason score (N; %) | ||
| ≤6 | 930 | 53 % |
| 7 | 752 | 42 % |
| ≥8 | 90 | 5 % |
| NCCN risk groups (N; %) | ||
| Low | 748 | 42 % |
| Intermediate | 855 | 48 % |
| High | 169 | 10 % |
| PPC (N, %) | ||
| <34 % | 883 | 50 % |
| ≥34 % | 883 | 50 % |
| CAPRA score> | ||
| 0-2 | 759 | 43 % |
| 3-5 | 811 | 46 % |
| 6-10 | 194 | 11 % |
| BMI | ||
| Median (range) | 28.2 | 13.9–52.5 |
| Diabetes (N; %)> | ||
| Yes | 272 | 15 % |
| No | 1500 | 85 % |
| Statin use (N; %)> | ||
| Yes | 762 | 43 % |
| No | 1010 | 57 % |
| CVD (N; %) | ||
| Yes | 629 | 35 % |
| No | 1143 | 65 % |
| HTN (N; %) | ||
| Yes | 815 | 46 % |
| No | 957 | 54 % |
| Lymphocytes (103 cells/μL) | ||
| Median (range) | 1.7 | 0.4–16 |
| Neutrophils (103 cells/μL) | ||
| Median (range) | 4.5 | 0.9–12 |
| NLR | ||
| Median (range) | 3.0 | 0.1–18.4 |
| Treatment characteristics | ||
| Radiotherapy | ||
| HDR brachytherapy | 52 | 3 % |
| LDR brachytherapy | 901 | 51 % |
| EBRT | 815 | 46 % |
| Androgen deprivation> | ||
| Non | 1551 | 87 % |
| Yes | 221 | 13 % |
PSA = prostate-specific antigen; AJCC = American Joint Committee on Cancer; NCCN = National Comprehensive Cancer Network; PPC = percentage of positive cores at prostate biopsies; CAPRA = Cancer of the Prostate Risk Assessment score, BMI = body mass index; CVD = cardiovascular disease; HTN = hypertension. >HDR = High dose rate; LDR = Low dose rate. Lymphocytes, neutrophils and NLR were available for 950 patients; BMI was available for 544 patients; data was available for entire cohort (1772 patients) for all the other factors.